Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is far larger — about 2.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| TNGX | VUSB | |
|---|---|---|
Market Cap | $3.75B | $10.20B |
Volume | 9,619,106 | 1,227,697 |
Sector | Health | Leveraged / Inverse |
52-Week High | $32.90 | $50.03 |
52-Week Low | $7.50 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
